Related Experiment Video
Updated: Jul 25, 2025
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer
Ana Oaknin1, Lucy Gilbert2, Anna V Tinker3
1Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital.
What Is This Summary About?:
Dostarlimab, also known by the brand name JEMPERLI, is a medicine that can be used to treat certain types of endometrial cancer. GARNET is an ongoing phase 1 clinical study that is testing the safety and side effects of dostarlimab and the best way to administer it to patients. The results presented in this summary are from a time point in the middle of the study.
What Were The Results?:
The results from the GARNET study published in 2022 showed how well dostarlimab worked for people participating in the study. Dostarlimab was found to reduce the size of tumors in patients with certain types of endometrial cancer. The patients treated with dostarlimab had side effects that could be managed and few severe side effects.
What Do The Results Mean?:
The results of the GARNET study led to dostarlimab being approved to treat patients with certain types of endometrial cancer. For patients with advanced-stage endometrial cancer, or endometrial cancer that has come back after chemotherapy (recurrent), there are few treatment options. The results suggest that dostarlimab may provide long-term benefits for these patients.
Insights
Dostarlimab (JEMPERLI) demonstrated significant tumor reduction in endometrial cancer patients. This immunotherapy offers manageable side effects and potential long-term benefits for those with advanced or recurrent disease.
Area of Science:
- Oncology
- Clinical Pharmacology
- Immunotherapy
